Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Diuretics · 1 trial · 1 indication
The proportion of study days a PtIS is based on the subjects' daily pressure state
| Arm | Type | Description |
|---|---|---|
| Daily diuretic adjustment | OTHER | Daily adjustments of diuretics and associated supplements based on cardiac filling pressures. |
| Name | Type | Description |
|---|---|---|
| Diuretics | DRUG | Daily adjustments of diuretics and associated supplements based on cardiac filling pressures. |
Inclusion Criteria: * Patients implanted with a Chronicle IHM device (Model 9520, Model 9520B) or Chronicle ICD device (Model 7286) * Patients who have been prescribed daily diuretic therapy for the management of heart failure * Patients currently participating in the COMPASS-HF Extension Phase Stu...
Top 20 of 31 competitors
Diuretics are being studied for use in Heart Failure. The investigational small molecule is in Phase 2 clinical development for this cardiovascular condition. A completed Phase 2 trial evaluated the feasibility of an integrated patient care system using daily filling pressures in patients with heart failure.
Diuretics is being developed by Rhythm Pharmaceuticals, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker RYTM. The company is conducting clinical research on this small molecule for the treatment of heart failure.
Diuretics is in Phase 2 clinical development for Heart Failure. It is an investigational small molecule and has not been approved by regulatory authorities. A Phase 2 clinical trial has been completed, and the drug remains under investigation for this indication.
Diuretics has one completed Phase 2 clinical trial, NCT01370564, titled 'Feasibility of an Integrated Patient Care (IPC) System Using Daily Filling Pressures.' This trial enrolled 21 participants with Heart Failure in the United States and was not randomized or blinded.
Diuretics is not FDA approved. It is an investigational small molecule currently in Phase 2 clinical development for Heart Failure. The drug has completed one Phase 2 trial, but approval status has not been established, and it remains under clinical investigation.